BSEConcord Drugs LtdMinimalNeutral
Announced Tue, 14 Oct · 14:55 IST

Certificate Under Reg.74(5)

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Concord Drugs Ltd has submitted to BSE a compliance certificate from its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, under SEBI Regulation 74(5). The certificate covers the quarter ended 30 September 2025 and confirms that within 15 days of receiving security certificates from the depository participant, the R&T Agent completed the dematerialization of securities, cancelled the physical certificates, and updated the depository's name as the registered owner in the company's records. The filing is signed by Managing Director Nagireddy (DIN: 01764665).

Likely market impact

This is a routine regulatory compliance filing with no material impact on the company's financials or operations. It confirms standard procedural compliance for share dematerialization and is unlikely to move the stock price.